Although the gut renews itself constantly, its stem cells accumulate age-related molecular changes that quietly alter how ...
Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...
Abstract: Cerebral stroke, as a disease resulting from cerebral circulatory disorders, continues to have a stubbornly high incidence rate. With the ongoing advancements in rehabilitation technology, ...
Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA ® (narsoplimab-wuug), the first and only therapy indicated for ...
Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. The stock was up 78% to $15.60 on Wednesday and was briefly paused ...
Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
Molecular Otolaryngology and Renal Research Laboratories, University of Iowa, Iowa City, IA, United States C3 Glomerulopathy (C3G) is a renal disease mediated primarily by dysregulation of the ...
Abstract: Molecular communication (MC) is a bio-inspired communication paradigm that utilizes molecules to transfer information and offers a robust framework for understanding biological signaling ...
Pentraxins, which constitute a family of evolutionarily conserved pattern recognition molecules, are categorized into short and long branches. The long pentraxin 3 (PTX3) is a key member of the long ...
This study presents a valuable advance in reconstructing naturalistic speech from intracranial ECoG data using a dual-pathway model. The evidence supporting the claims of the authors is solid, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results